We are live on ! Find out more
JJIJ

Johnson & Johnson Innovation - JJDC Portfolio holdings

AUM $978M
1-Year Est. Return 102.17%
This Fund
S&P 500
This Quarter Est. Return
+0.88%
1 Year Est. Return
+102.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$497M
AUM Growth
-$12.1M
Cap. Flow
+$3.26M
Cap. Flow %
0.66%
Top 10 Hldgs %
98.72%
Holding
16
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
ACET icon
Adicet Bio
ACET
+$10.5M

Top Sells

Rank Stock Value
1
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$6.95M
2
GNCA
Genocea Biosciences, Inc.
GNCA
+$264K

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Technology 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$11.7B
$140M 28.26%
3,260,869
– –
FATE icon
2
Fate Therapeutics
FATE
$265M
$135M 27.18%
3,379,064
– –
LEGN icon
3
Legend Biotech
LEGN
$3.68B
$50.3M 10.12%
1,629,173
– –
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.64B
$47.9M 9.64%
2,449,183
– –
FUSN
5
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$44.1M 8.88%
3,670,516
– –
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.1B
$38.4M 7.72%
2,898,550
– –
PHGE icon
7
BiomX
PHGE
$1.94M
$13.5M 2.72%
11,228
– –
ACET icon
8
Adicet Bio
ACET
$73.7M
$7.88M 1.59%
+41,417
New +$10.5M
PRVB
9
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$7.38M 1.48%
574,973
-550,000
-49% -$6.95M
PHAS
10
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.64M 1.14%
1,607,044
– –
ALDX icon
11
Aldeyra Therapeutics
ALDX
$92.3M
$4.41M 0.89%
594,834
– –
CSLT
12
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$917K 0.18%
811,295
– –
TCON
13
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$434K 0.09%
4,200
– –
GYRE icon
14
Gyre Therapeutics
GYRE
$668M
$288K 0.06%
8,927
– –
SENS icon
15
Senseonics Holdings Inc
SENS
$259M
$204K 0.04%
26,282
– –
GNCA
16
DELISTED
Genocea Biosciences, Inc.
GNCA
$99K 0.02%
43,177
-100,787
-70% -$264K

Similar funds

NNP
Nachman Norwood & Parrott Greenville, South Carolina $984M AUM 33.8% 1-Year Est. Return
BAWC
Black-and-white Capital Los Angeles, California $967M AUM 94.03% 1-Year Est. Return
RP
RR Partners New York $929M AUM 110.28% 1-Year Est. Return
NIA
Northstar Investment Advisors Denver, Colorado $755M AUM 37.8% 1-Year Est. Return
SCM
Snow Capital Management Sewickley, Pennsylvania $703M AUM 76.26% 1-Year Est. Return
EMG
Ellington Management Group Old Greenwich, Connecticut $676M AUM 23.65% 1-Year Est. Return
APA
Allegiant Private Advisors Sarasota, Florida $618M AUM
HFA
Hoover Financial Advisors Malvern, Pennsylvania $562M AUM 37.9% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's Q3 2020 Portfolio in Review

As of Q3 2020, Johnson & Johnson Innovation - JJDC held 16 positions worth $497M, down 2.4% from $509M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Johnson & Johnson Innovation - JJDC's Q3 2020 filing shows 1 new and 2 reduced positions. Its largest new stake was Adicet Bio: 41,417 shares worth $7.88M. The largest sale was Provention Bio, Inc. Common Stock, an estimated $6.95M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.

  • Johnson & Johnson Innovation - JJDC's largest Q3 2020 buy was Adicet Bio: 41,417 shares worth $7.88M.
  • Johnson & Johnson Innovation - JJDC's biggest Q3 2020 reduction was Provention Bio, Inc. Common Stock, cutting an estimated $6.95M.
  • Johnson & Johnson Innovation - JJDC's ten largest holdings make up 99% of its $497M portfolio in Q3 2020.
  • Johnson & Johnson Innovation - JJDC opened 1 new position and closed 0 in Q3 2020.
  • Johnson & Johnson Innovation - JJDC's portfolio value fell 2.4% quarter-over-quarter to $497M.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q3 2020, filed 3 Nov 2020.